Debunking Safety & Efficacy Concerns Surrounding Targeting Wild Type KRAS to Induce Tumor Regression
Time: 8:30 am
day: Workshop A
Details:
Wild type KRAS continues to present a huge challenge in selectively targeting mutant variants implicated in cancer due to its structural similarity and essential cellular functions. Debate surrounds the feasibility and safety of directly targeting wild type KRAS, with concerns over potential off-target effects. Despite advances in structural and functional studies, these findings are yet to translate into clinically viable therapies drawing an increasing need for thought leaders to debate the potential consequences and mitigations.
This workshop will discuss:
• Can we target wild type KRAS? If so, can we differentiate between active and inactive states?
• How can we minimize toxicity in RAS targeted therapies?
• How to develop robust pre-clinical models to assess the efficacy and safety of wild type KRAStargeting agents
• How to combine wild type KRAS inhibitors with other therapeutic agents?
